Favipiravir drug working better on Covid
patients Hyderabad: City-based pharma firm Raghava Life Sciences Pvt Limited (RLS), which is into API production,
on Wednesday claimed
Favipiravir antiviral drug has been producing better results in treating Covid-19 patients compared to Remdesivir which is current under clinical trials in the US.
The clinical trials done using Favipiravir have so far shown positive results.
Published results of a clinical trial of Favipiravir indicate that out of 80 patients, 35 who took the drug demonstrated significantly shorter viral clearance time compared to those who didn’t. The recovery period was shortened by four days from 11,
Lohit Reddy P, Director, RLS, said in a statement.
The seven-day day clinical recovery rate also increased from 55.86 per cent to 71.43 per cent, he added.
Reddy said that RLS is one of the first few companies in India to commercialise Favipiravir API (active pharmaceutical ingredient).